Quantcast

Latest Bristol-Myers Squibb Stories

2014-06-19 10:12:13

Washington University in St. Louis Researchers have identified the first genetic variations linked to race that begin to explain a higher risk of death among some African American and Caucasian patients taking the anti-clotting drug clopidogrel (Plavix) after a heart attack. These variants increased patients’ risk of dying in the year following a first heart attack, but they appeared to do so for different reasons depending on race, according to a study at Washington University...

2014-06-18 12:37:20

LONDON, June 18, 2014 /PRNewswire/ -- Reportbuyer.com has added a new market research report: Pharma Leader Series: Top 25 Ophthalmic Drug Manufacturers 2014-2024http://www.reportbuyer.com/pharma_healthcare/therapeutic/pharma_leader_series_top_25_ophthalmic_drug_manufacturers_2014_2024.html Report DetailsNew study shows you commercial prospects for leading eye drug producersWhat does the future hold for top companies in the pharma ophthalmics industry? Visiongain's brand new report...

2014-06-17 08:29:20

JACKSONVILLE, Florida, June 17, 2014 /PRNewswire/ -- NGA Human Resources, a leader in Global HR and Payroll, today announced it has been selected by global biopharmaceutical company Bristol-Myers Squibb (NYSE: BMY) to provide Payroll and related Workforce Administration Services for its employees in North America. As part of the multiyear agreement focused on the U.S., Canada, and Puerto Rico, NGA will execute and deliver Bristol-Myers Squibb's payroll via comprehensive...

2014-06-12 23:00:57

Health Canada has reinstated Biolyse Pharma’s Establishment Licence (EL) after sending in a team of inspectors to look at manufacturing within the St.Catharines based Pharmaceutical. The new team of inspectors found Biolyse to be in compliance with Canadian Good Manufacturing Practices (GMP) and assigned the company a "C" (conformance) rating. St.Catharines, Ontario (PRWEB) June 12, 2014 The Establishment Licensing Unit of Health Canada announced today that as a result of a...

2014-06-12 08:29:51

YARDLEY, Pa., June 12, 2014 /PRNewswire/ -- OptiNose, a global specialty pharmaceuticals company, today announced three appointments to the Company's senior management team. This expansion of the executive leadership will help drive the Company forward in its mission to introduce new and valuable treatment options to the market utilizing its novel Bi-Directional(TM) Breath Powered(TM) Delivery Technology. The recently appointed executives have served at some of the most prestigious...

2014-06-10 12:30:30

LONDON, June 10, 2014 /PRNewswire/ -- Reportbuyer.com has added a new market research report:Non-small cell lung cancer: Game changing immunotherapies to revolutionise treatment - KOL Insighthttp://www.reportbuyer.com/pharma_healthcare/diseases/non_small_cell_lung_cancer_game_changing_immunotherapies_revolutionise_treatment_kol_insight.html Change is coming to the NSCLC treatment algorithm--and it's coming soon. Revolutionary new immunotherapies, more personalised treatment choices...

2014-06-04 08:34:06

LONDON, June 4, 2014 /PRNewswire/ -- Reportbuyer.com has added a new market research report: Hepatitis Drugs and Vaccines: World Market 2013-2023http://www.reportbuyer.com/pharma_healthcare/therapeutic/hepatitis_drugs_vaccines_world_market_2013_2023.html Report DetailsYour guide to sales outlooks and R&D for hepatitis treatmentsWhere are hepatitis medicines going? Visiongain's updated report predicts revenues there from 2013 to 2023. It also explains trends in that business and...

2014-06-03 11:21:00

University of Texas M. D. Anderson Cancer Center Early but promising results lead to Phase II national trial In an aggressive disease known for poor response rates, researchers from The University of Texas MD Anderson Cancer Center found patients with advanced colorectal cancer responded well to a combination therapy of the drugs vermurafenib, cetuximab and irinotecan. The Phase I trial, presented Saturday, May 31 in a poster discussion at the American Society of Clinical Oncology's...

2014-06-02 08:29:32

Phase 1 Study Evaluating Talimogene Laherparepvec Plus Ipilimumab Showed Tolerability at Doses Administered THOUSAND OAKS, Calif., June 2, 2014 /PRNewswire/ -- Amgen (NASDAQ: AMGN) today announced new data from two key clinical trials that support the potential of talimogene laherparepvec, a novel, investigational oncolytic immunotherapy, as both a single agent and as part of a combination regimen in patients with metastatic melanoma. The findings were presented at the 50th...

2014-05-31 08:21:10

Study Shows Improved Survival Benefit in Panitumumab Arm THOUSAND OAKS, Calif., May 31, 2014 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced results from the Phase 2 PEAK study that reinforce the improved overall survival (OS) benefit of panitumumab (Vectibix(®)) when used in combination with FOLFOX, an oxaliplatin-based chemotherapy regimen, compared to bevacizumab (Avastin(®)) plus FOLFOX as first-line treatment in patients with wild-type RAS metastatic colorectal cancer (mCRC). The...


Word of the Day
abrosia
  • Wasting away as a result of abstinence from food.
The word 'abrosia' comes from a Greek roots meaning 'not' and 'eating'.